Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was achieved by 20% of patients. Endoscopic improvement was achieved by 30%.
The primary endpoint was statistically significant compared with baseline, with p<0.0001. That supports further investigation, while the absence of a control arm leaves the size of the treatment effect unresolved.
Bull Case
Spyre Therapeutics, Inc. reported activity in a population in which 41% had previously received advanced therapies. Improvement across histology, clinical remission, and endoscopy provides several reasons to continue development. Prior treatment exposure adds relevance, although the overall results do not establish efficacy specifically within that subgroup.
SPY003 is an investigational antibody targeting IL-23, an inflammatory signaling protein, and is engineered for an extended half-life. For Spyre Therapeutics, Inc., the opportunity is to combine disease control with less frequent maintenance dosing. If sustained efficacy and convenient dosing are confirmed, the treatment could offer a differentiated patient experience.
Randomized, placebo-controlled Part B is enrolling and evaluating monotherapies and pairwise combinations, with induction results expected in 2027. Comparing combinations with their individual components could show whether adding another mechanism produces enough benefit to justify greater treatment complexity.
Spyre Therapeutics, Inc. also has resources to pursue those studies. Cash, cash equivalents, and marketable securities totaled approximately $1.15 billion at June 30, 2026. Management projected funding into the second half of 2029, providing a financial buffer around the expected Part B readout.
Bear Case
The central limitation is the uncontrolled design. Patient selection, background treatment, and fluctuations in disease activity could influence the observed improvement. A small p-value for change from baseline does not establish superiority over placebo or another therapy.
The 20% clinical-remission rate and 30% endoscopic-improvement rate also represent different outcomes. Neither establishes lasting disease control, and most patients did not achieve clinical remission by week 12. Longer follow-up must demonstrate whether benefits persist through maintenance treatment.
Spyre Therapeutics, Inc. reported serious adverse events in three patients, or 7%, with none assessed as treatment-related. Five patients, or 11%, experienced severe adverse events of Grade 3 or higher, all assessed as unrelated to treatment. Severe and serious events are separate classifications. No adverse events led to treatment discontinuation. These findings support continued testing, but this small, 12-week dataset provides limited information about uncommon events or the safety of combination treatment.
Development remains expensive. Spyre Therapeutics, Inc. used $69.9 million of operating cash during the second quarter. A substantial cash balance supports execution, but its investment value depends on producing convincing controlled results.
Hedge Fund Sentiment
The filings available so far reflect positions held before Spyre Therapeutics, Inc. reported its SPY003 SKYLINE Part A results. Insider Monkey’s database showed 57 hedge funds holding Spyre Therapeutics, Inc. at the end of 2Q2026, up from 36 funds three months earlier.
Conclusion
Spyre Therapeutics, Inc. generated an encouraging early signal and has funding to investigate it further. The evidence supports advancing development, while comparative efficacy remains unproven.
Part B will test whether the observed activity exceeds placebo and whether combinations improve on their components. Durable remission, added efficacy, and acceptable safety will determine whether SPY003 becomes a valuable treatment platform.
READ NEXT: Vertiv (VRT) Signed a Deal Worth Up to $2.6B for UtilityInnovation. Can Faster Power Deployment Justify the Contingent Consideration? and Asana (ASAN) Reached a 10% Non-GAAP Operating Margin. Can Agentic Products Restore Expansion?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center